Verve Ventures
Verve Ventures is a European startup investment platform based in Zug, Switzerland, that focuses on providing qualified and institutional investors access to high-potential ventures. Founded in 2010, the firm has invested over EUR 130 million in more than 140 startups across various sectors, including science, technology, clean energy, and digital health. It operates a fully digital platform allowing private investors to build diversified portfolios with investments starting at EUR 10,000. Verve Ventures boasts a community of 5,000 registered investors, including family offices and pension funds, and is backed by Zürcher Kantonalbank, one of Switzerland's largest banks. The firm employs a dedicated team of investment professionals who rigorously screen thousands of startups annually to select the top 1% for investment. Beyond capital, Verve Ventures supports startups with essential resources such as hiring and client introductions, facilitating their growth and success in competitive markets.
Past deals in Health Diagnostics
Aktiia
Series B in 2025
Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.
Poppins
Venture Round in 2025
Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.
Orakl Oncology
Seed Round in 2024
Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.
Retinai
Series B in 2024
RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.
Neo Medical
Series B in 2024
Neo Medical SA is a medical technology company based in Villette, Switzerland, with additional offices in Germany, France, and the United States. Founded in 2013, the company specializes in developing, manufacturing, and commercializing non-constraint thoraco-lumbar spinal fusion systems for spinal surgery. Its flagship product, the Neo Pedicle Screw System, offers a range of functionalities such as reduction, compression, distraction, and screw augmentation, addressing various pathologies including degenerative conditions, tumors, and trauma. Neo Medical aims to enhance the efficiency of healthcare delivery by providing versatile and high-quality surgical solutions, thereby contributing to the ongoing pursuit of healthcare cost optimization.
Retinai
Series A in 2024
RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.
Aktiia
Series A in 2024
Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.
Poppins
Venture Round in 2023
Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.
Orakl Oncology
Seed Round in 2023
Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.
MedTrace Pharma
Venture Round in 2023
MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.
Therapixel
Series B in 2022
Therapixel SA is a company based in Valbonne, France, with additional locations across multiple countries, including Australia and China. Founded in 2013, Therapixel specializes in designing and developing medical image analytics software for surgeons, leveraging artificial intelligence to enhance surgical procedures. Their product portfolio includes Radvise, an automatic image reading solution; Fluid, a touchless medical image navigation system for surgery; Anywhere, a post-processing workstation; and CD-Feed, a solution for importing CDs from outpatient imaging exams. The company also focuses on AI-based software for breast cancer detection and characterization, providing healthcare professionals with pertinent information to support decision-making during surgeries while adhering to sterility constraints.
Sleepiz
Series A in 2022
Sleepiz AG, founded in 2018 and headquartered in Zurich, Switzerland, specializes in manufacturing a non-contact sleep disorder-screening device. The product monitors breathing, heart rate, and body movements with medical-grade accuracy using wireless millimeter wave technology, sensor fusion, and artificial intelligence. This device is designed to be placed on the bedside table for easy use, enabling healthcare professionals to monitor patients' sleep patterns from home. Sleepiz aims to facilitate long-term monitoring of chronic diseases, allowing for faster intervention and improved treatment outcomes.
Medimaps Group
Venture Round in 2021
Medimaps Group is a developer of medical insights software focused on enhancing the diagnosis and treatment of osteoporosis by assessing bone microarchitecture. The company designs tools that utilize artificial intelligence to analyze imaging data from DXA, X-ray, and projected CT images, enabling healthcare professionals to evaluate bone texture effectively. By employing the trabecular bone score technique, Medimaps Group provides critical quantitative information that aids physicians in selecting optimal treatment options and monitoring patient outcomes. The company is also exploring future applications of its technology in the dental and orthopedic fields, further broadening its impact on patient care.
PathoQuest
Series B in 2021
PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.
Aktiia
Series A in 2021
Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.
Sleepiz
Series A in 2021
Sleepiz AG, founded in 2018 and headquartered in Zurich, Switzerland, specializes in manufacturing a non-contact sleep disorder-screening device. The product monitors breathing, heart rate, and body movements with medical-grade accuracy using wireless millimeter wave technology, sensor fusion, and artificial intelligence. This device is designed to be placed on the bedside table for easy use, enabling healthcare professionals to monitor patients' sleep patterns from home. Sleepiz aims to facilitate long-term monitoring of chronic diseases, allowing for faster intervention and improved treatment outcomes.
EarlySight
Seed Round in 2021
EarlySight SA is a Swiss medical device company established in 2016 and headquartered in Lausanne. It specializes in developing advanced imaging technology to aid in the early detection and treatment of eye diseases. The company's innovative eye fundus camera utilizes cellular-level imaging and transscleral illumination to provide detailed images of the retina, allowing for the detection of minor structural changes. This technology enables eye specialists to monitor treatment effects rapidly and non-invasively, enhancing their ability to visualize the morphology of retinal cells. EarlySight aims to bring its cutting-edge solutions to clinics, thereby improving patient outcomes in ophthalmology.
Perfood
Series A in 2020
Perfood GmbH, founded in 2017 and headquartered in Lübeck, Germany, specializes in digital therapeutics focused on personalized nutrition. The company employs advanced algorithms and a proprietary dataset to develop therapeutic solutions that aid in weight management and migraine relief. By leveraging sensors, lab results, and comprehensive analyses, Perfood creates tailored dietary plans that address the root causes of health issues. Its digital platform delivers these personalized interventions in an engaging manner, ensuring accessibility for all patients. The company's approach aims to provide drug-like effectiveness without the side effects associated with conventional medications.
Neo Medical
Series A in 2020
Neo Medical SA is a medical technology company based in Villette, Switzerland, with additional offices in Germany, France, and the United States. Founded in 2013, the company specializes in developing, manufacturing, and commercializing non-constraint thoraco-lumbar spinal fusion systems for spinal surgery. Its flagship product, the Neo Pedicle Screw System, offers a range of functionalities such as reduction, compression, distraction, and screw augmentation, addressing various pathologies including degenerative conditions, tumors, and trauma. Neo Medical aims to enhance the efficiency of healthcare delivery by providing versatile and high-quality surgical solutions, thereby contributing to the ongoing pursuit of healthcare cost optimization.
Pregnolia
Series A in 2020
Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.
Aktiia
Seed Round in 2020
Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.
OncoDNA
Series B in 2020
OncoDNA is a theranostic and genomic company that specializes in precision medicine for cancer and genetic diseases. Founded by a team with over 60 years of experience in medical diagnostics, the company focuses on providing clinical guidance for the treatment and real-time monitoring of late-stage cancer patients. OncoDNA supports researchers and biopharma companies in navigating the complexities of molecular biology, facilitating research and drug development in oncology. With its commitment to delivering precision medicine, OncoDNA aims to enhance treatment outcomes and improve the management of cancer and genetic disorders.
PathoQuest
Series A in 2019
PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.
Retinai
Seed Round in 2019
RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.
Piavita
Series A in 2019
Piavita AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing advanced technology for the veterinary industry. The company has created a compact, matchbox-sized wearable device that accurately measures vital medical data from pets, including horses, without the need for clipping fur or extensive preparation. This innovative system is complemented by a web-based application that enables real-time monitoring and historical tracking of vital signs, improving the diagnostic capabilities available to veterinarians. By providing reliable insights into pet health and facilitating better communication between pet owners and veterinary professionals, Piavita aims to lead the digital transformation of veterinary care, addressing the gaps in current veterinary practices and enhancing the overall wellbeing of animals.
Luciole Medical
Series A in 2018
Luciole Medical AG is a Swiss medical technology company that specializes in the design and manufacture of brain oxygenation monitoring systems. Founded in 2017 and based in Zurich, the company has developed a platform that accurately measures the levels of oxygenated and deoxygenated hemoglobin, as well as cerebral blood flow and other critical parameters. Its product lineup includes RheoPatch, a non-invasive sensor applied to the skin to assess oxygen metabolism and blood flow; RheoSens, an implantable probe that measures various cerebral metrics; RheoLity, which offers software for data display, analysis, and patient management; and RheoControl, which connects to medical monitors for data visualization. Luciole Medical's systems enable healthcare professionals to monitor cerebral oxygenation effectively, providing crucial insights into the patient's brain health.
Pregnolia
Seed Round in 2018
Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.
DBS System
Series A in 2017
DBS System SA is a medtech company based in the Swiss Health Valley that specializes in the production of HemaXis™ blood collection devices. The company utilizes advanced microfluidic technology to create innovative devices designed for the less invasive, safer, and more efficient collection and preparation of blood samples. HemaXis devices facilitate plasma and serum extraction with precision and in a standardized format, significantly enhancing the capabilities of dried blood spot samples in bioanalysis. By streamlining blood collection processes, DBS System aims to support health monitoring and testing while contributing to the advancement of personalized medicine and big data initiatives.
Piavita
Seed Round in 2016
Piavita AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing advanced technology for the veterinary industry. The company has created a compact, matchbox-sized wearable device that accurately measures vital medical data from pets, including horses, without the need for clipping fur or extensive preparation. This innovative system is complemented by a web-based application that enables real-time monitoring and historical tracking of vital signs, improving the diagnostic capabilities available to veterinarians. By providing reliable insights into pet health and facilitating better communication between pet owners and veterinary professionals, Piavita aims to lead the digital transformation of veterinary care, addressing the gaps in current veterinary practices and enhancing the overall wellbeing of animals.
Clinpal
Series B in 2014
Clinpal is a technology-driven company that specializes in enhancing the efficiency and effectiveness of clinical trials through its cloud-based platform. The platform is designed to support virtual, hybrid, and direct-to-patient studies by streamlining patient recruitment, engagement, retention, and data acquisition throughout the clinical trial process. Clinpal offers a comprehensive workflow and communication engine that connects all stakeholders, including patients, clinical research associates, and sponsors, thereby improving collaboration and data quality in real time. Its intelligent data hub consolidates biometric data reported by patients or clinicians, ensuring that high-quality information is readily available. Clinpal’s scalable architecture and flexible licensing options make it suitable for a diverse range of clinical trials, ultimately helping healthcare clients achieve better trial outcomes and productivity.
MEDUDEM
Seed Round in 2011
MEDUDEM Corp. is a company in the digital health sector that focuses on the improvement of collaboration and interaction of all participants involved around chronic diseases (CCM). On the basis of its readily available web- and mobile-based solutions Care Integrator® and Healthbrain®, MEDUDEM Corp. improves collaboration and exchanges between medical professionals and patients, as well as third-party organizations. This provides clear advantages and synergetic benefits for all parties in and around the healthcare market and ensures the interaction and communication in a simple, fast and comprehensive way and manner.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.